Relay Therapeutics Inc (RLAY) Key Ratios
$18.78
As on 04-Sep-2026 12:40EDT
Market cap
$4,113 Mln
Revenue (TTM)
$10 Mln
P/E Ratio
--
P/B Ratio
4.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -88.33 | -48.30 | 23.86 | 122.31 | -34.28 |
| EBIT | -14.21 | -18.94 | 8.19 | 7.44 | -195.44 |
| Net Profit | -14.21 | -18.94 | 8.19 | 5.36 | 3.79 |
| EPS | -1.26 | -0.42 | 19.43 | 13.42 | 7.20 |
| Book Value | -- | -- | -28.90 | -25.07 | -17.15 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -2,379.96 | -7,430.15 | -2,763.64 | -1,800.58 | -3,854.04 |
| Net Margin
| -- | -6,148.17 | -2,763.64 | -- | -- |
| Return on equity
| -41.82 | -40.14 | -39.26 | -41.12 | -44.15 |
| Return on Capital
| -39.30 | -38.12 | -- | -38.78 | -41.39 |
| Return on Assets
| -37.20 | -35.88 | -32.15 | -37.05 | -39.38 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.06 | 0.06 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
ROE
-39.26
Higher than Peers by 1.14
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
-39.26
|
-41.12
|
-44.15
|
-40.18
|
-31.44
|
-43.81
|
|||||
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
--
|
ROA
-32.15
Lower than Peers by 1.17
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
-32.15
|
-37.05
|
-39.38
|
-35.19
|
-27.56
|
-40.25
|
|||||
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-2,763.64
Lower than Peers by 2,680.02
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
-2,763.64
|
-1,800.58
|
-3,854.04
|
-1,485.25
|
-22,516.44
|
-7,494.45
|
|||||
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-2,763.64
Lower than Peers by 2,670.97
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
-2,763.64
|
-1,800.58
|
-3,374.72
|
-1,338.66
|
-2,857.37
|
-9,438.96
|
|||||
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
Revenue Growth
23.86
Lower than Peers by 30.09
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
23.86
|
0.53
|
-0.61
|
17.50
|
-0.54
|
-0.96
|
|||||
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
8.19
Higher than Peers by 8.99
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
8.19
|
28.31
|
-1.65
|
-22.02
|
-36.98
|
-306.85
|
|||||
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
8.19
Higher than Peers by 15.49
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
8.19
|
18.13
|
1.25
|
-17.72
|
20.16
|
-594.25
|
|||||
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
19.43
Higher than Peers by 4.78
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
19.43
|
0.20
|
0.28
|
-0.16
|
0.32
|
-5.09
|
|||||
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
--
|
Book Value Growth
12.89
Higher than Peers by 23.06
Year on year growth in book value per share
Solvency
Debt to Equity
--
--
Total debt / Net worth
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
Current Ratio
18.27
Higher than Peers by 12.46
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
18.27
|
22.61
|
15.95
|
25.44
|
16.00
|
40.14
|
|||||
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
18.27
Higher than Peers by 12.57
(Current Assets - Inventory) / Current Liabilities and Provisions
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
Asset Turnover
0.01
Lower than Peers by 0.05
Sales / Average Total Assets
Receivable days
--
--
Average Debtors / Sales * 365
Inventory Days
--
--
Average Inventory / Sales * 365
Payable days
--
--
Average Creditors / Cost of goods sold * 365
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
Price / Book Value
4.78
Lower than Peers by 0.40
Current share price divided by book value per share in the latest financial year
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
EV/EBITDA
-0.80
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
Market Cap
4,113
Higher than Peers by 3,967
Current Share price multiplied by latest total number of shares outstanding